𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dose-dependent pharmacokinetics of aprindine in healthy volunteers

✍ Scribed by T. Kobari; T. Itoh; T. Hirakawa; H. Namekawa; T. Suzuki; T. Satoh; N. Iida; F. Ohtsu; H. Hayakawa


Publisher
Springer
Year
1984
Tongue
English
Weight
293 KB
Volume
26
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Single dose pharmacokinetics of sumatrip
✍ L. F. Lacey; E. K. Hussey; P. A. Fowler πŸ“‚ Article πŸ“… 1995 πŸ› Springer 🌐 English βš– 516 KB

Sumatriptan is classified as a vascular 5HT 1 receptor agonist and is effective in the acute treatment of migraine and cluster headache. Sumatriptan is available as an injection for subcutaneous administration and as a tablet for oral administration. The pharmacokinetics of sumatriptan differ depend

Single dose pharmacokinetics and bioavai
✍ Michael J. Lamson; John P. Sabo; Thomas R. Macgregor; Joseph W. Pav; Lois Rowlan πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 2 views

The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.

Pharmacokinetics of rufloxacin in health
✍ G. Segre; D. Cerretani; L. Moltoni; R. Urso πŸ“‚ Article πŸ“… 1992 πŸ› Springer 🌐 English βš– 446 KB

The plasma and urine kinetics of rufloxacin were assessed in healthy volunteers after single (100, 200, 400 and 800 mg) and multiple (300 mg followed by 150 mg daily, Group 1, and 400 mg followed by 200 mg daily, Group 2) oral doses. The kinetics of a single oral dose of 800 mg was assessed in fasti

Single dose pharmacokinetics of HEPP, a
✍ Dinora F. GonzΓ‘lez-Esquivel; Francisco Rubio-Donnadieu; Guillermo Carvajal S.; H πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 128 KB πŸ‘ 2 views

The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of